Jorizzo Joseph, Dinehart Scott, Matheson Robert, Moore Jeffrey K, Ling Mark, Fox Terry L, McRae Scott, Fielder Sandra, Lee James H
Wake Forest University School of Medicine, Department of Dermatology, Medical Center Blvd, Winston-Salem, NC 27157, USA.
J Am Acad Dermatol. 2007 Aug;57(2):265-8. doi: 10.1016/j.jaad.2007.01.047. Epub 2007 May 18.
A shorter dosing regimen of imiquimod for the treatment of actinic keratosis may be effective, with long-term clinical benefits.
Imiquimod in one or two shorter courses of treatment was evaluated.
Patients with actinic keratosis lesions on the head applied imiquimod or vehicle cream 3x/wk for 4 weeks (course 1). Patients with remaining lesions received another course of treatment. Complete and partial clearance rates were evaluated after course 1, after course 2 (overall), and 1 year later.
Complete clearance rates were 26.8% (course 1) and 53.7% (overall). Partial clearance rates were 36.6% (course 1) and 61.0% (overall). One-year follow-up recurrence rates were 39% (imiquimod) and 57% (vehicle).
Blinded investigators may have been biased toward patients treated with imiquimod identified by treatment site reactions.
Imiquimod 3x/wk in one or two courses of treatment appears to be effective for the treatment of actinic keratoses on the head, providing long-term clinical benefits. Some recurrences do occur, so long-term follow-up is recommended.
采用较短疗程的咪喹莫特治疗光化性角化病可能有效，并具有长期临床益处。
评估一或两个较短疗程的咪喹莫特治疗效果。
头部患有光化性角化病皮损的患者每周3次外用咪喹莫特或赋形剂乳膏，共4周（疗程1）。仍有皮损的患者接受另一疗程治疗。在疗程1后、疗程2（总体）后及1年后评估完全清除率和部分清除率。
完全清除率在疗程1时为26.8%，总体为53.7%。部分清除率在疗程1时为36.6%，总体为61.0%。1年随访复发率在咪喹莫特组为39%，赋形剂组为57%。
设盲的研究者可能因治疗部位反应而对接受咪喹莫特治疗的患者存在偏倚。
每周3次外用咪喹莫特进行一或两个疗程的治疗似乎对头部光化性角化病有效，并具有长期临床益处。确实会发生一些复发情况，因此建议进行长期随访。
